Table 1 Clinical characteristics of the training set and the testing set
Training set ( n = 208) | Testing set ( n = 84) | p -value a | |
|---|---|---|---|
Age:median (1st Qu., 3rd Qu.) | 54.00(47.25,60.00) | 54.50(47.00,64.00) | 0.49 |
CA125:median (1st Qu., 3rd Qu.) | 867.00(511.00,1717.75) | 867.00(319.75,1787.75) | 0.30 |
Surgical resection status | 0.65 | ||
R0 (no residual tumor) | 119(57.21%) | 50(59.52%) | |
R1 (residual tumor ≤ 1 cm) | 42(20.19%) | 19(22.62%) | |
R2 (residual tumor > 1 cm) | 47(22.60%) | 15(17.86%) | |
FIGO stage determined surgically (%) | 0.93 | ||
IIB | 3(1.44%) | 1(1.19%) | |
IIIA | 6(2.88%) | 1(1.19%) | |
IIIB | 20(9.62%) | 9(10.71%) | |
IIIC | 119(57.21%) | 45(53.57%) | |
IVA | 33(15.97%) | 16(19.05%) | |
IVB | 27(12.98%) | 12(14.29%) | |
Ascites volume | 1500.00(300.00,3000.00) | 1000.00(200.00,3750.00) | 0.50 |
Ascites_character | 0.38 | ||
No ascites | 9(4.33%) | 6(7.14%) | |
Bloody | 63(30.29%) | 20(23.81%) | |
Non-bloody | 136(65.38%) | 58(69.05%) | |
Survival time:median (1st Qu., 3rd Qu.) | |||
PFS | 644.50(413.75,902.50) | 657.00(422.00,902.00) | 0.79 |
OS | 1021.50(724.25,1630.00) | 989.50(657.50,1729.75) | 0.44 |